Table 4.
Association of HDAC2 expression with various clinicopathological factors
| Characteristic | All cases | HDAC 2 low (IRS 0–4) | HDAC 2 intermediate (IRS 6–8) | HDAC 2 high (IRS 9–12) | P-valueχ2-test for trends |
|---|---|---|---|---|---|
|
All cases |
212 (100%) |
92 (43.4%) |
69 (32.5%) |
51 (24.1%) |
-- |
|
Histological type |
|
|
|
|
0.59 |
| Ductal carcinoma/Other |
180 (100%) |
80 (44.4%) |
56 (31.1%) |
44 (24.5%) |
|
| Lobular carcinoma |
27 (100%) |
10 (37%) |
10 (37%) |
7 (26%) |
|
|
Histological grade |
|
|
|
|
<0.001* |
| G1 |
60 (100%) |
34 (56.7%) |
20 (33.3%) |
6 (10%) |
|
| G2 |
92 (100%) |
39 (42.4%) |
32 (34.8%) |
21 (22.8%) |
|
| G3 |
55 (100%) |
17 (30.9%) |
14 (25.5%) |
24 (43.6%) |
|
|
Nodal status |
|
|
|
|
0.04* |
| negative |
130 (100%) |
66 (50.8%) |
36 (27.7%) |
28 (21.5%) |
|
| positive |
70 (100%) |
23 (32.9%) |
28 (40%) |
19 (27.1%) |
|
|
pT-Stage |
|
|
|
|
0.43 |
| pT1 |
117 (100%) |
52 (44.4%) |
41 (35%) |
24 (20.6%) |
|
| pT2/pT3 |
79 (100%) |
32 (40.5%) |
22 (27.9%) |
25 (31.6%) |
|
| pT4 |
10 (100%) |
5 (50%) |
3 (30%) |
2 (20%) |
|
|
Hormone receptor status |
|
|
|
|
0.02* |
| Hormone receptor positive |
163 (100%) |
73 (44.8%) |
59 (36.2%) |
31 (19%) |
|
| Hormone receptor negative |
43 (100%) |
17 (39.5%) |
7 (16.3%) |
19 (44.2%) |
|
|
HER2 status |
|
|
|
|
0.005* |
| negative |
178 (100%) |
83 (46.6%) |
55 (30.9%) |
40 (22.5%) |
|
| positive | 25 (100%) | 5 (20%) | 9 (36%) | 11 (44%) |